Trials / Completed
CompletedNCT05022693
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
An Open-Label, Single-Dose Pharmacokinetic Study of Liquid Subcutaneous Formulation of BIO89-100 in Subjects With Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- 89bio, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIO89-100 | Subcutaneous Injections |
Timeline
- Start date
- 2021-08-16
- Primary completion
- 2021-12-21
- Completion
- 2021-12-21
- First posted
- 2021-08-26
- Last updated
- 2022-03-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05022693. Inclusion in this directory is not an endorsement.